Fifth Third Bancorp’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Fifth Third Bancorp’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$671K	Buy	6,773 +213	+3%	+$19.2K	﹤0.01%	1923
2026 Q1	$569K	Buy	6,560 +5,393	+462%	+$472K	﹤0.01%	1982
2025 Q4	$99K	Hold	1,167	–	–	﹤0.01%	1198
2025 Q3	$84.7K	Hold	1,167	–	–	﹤0.01%	1290
2025 Q2	$76.5K	Sell	1,167 -94	-7%	-$6.12K	﹤0.01%	1252
2025 Q1	$89K	Buy	1,261 +52	+4%	+$3.61K	﹤0.01%	1194
2024 Q4	$79.5K	Buy	1,209 +7	+0.6%	+$482	﹤0.01%	1220
2024 Q3	$84.9K	Hold	1,202	–	–	﹤0.01%	1232
2024 Q2	$79.7K	Sell	1,202 -70	-6%	-$4.59K	﹤0.01%	1210
2024 Q1	$86.4K	Buy	1,272 +1,122	+748%	+$74.2K	﹤0.01%	1167
2023 Q4	$9.27K	Hold	150	–	–	﹤0.01%	1985
2023 Q3	$8.85K	Hold	150	–	–	﹤0.01%	1997
2023 Q2	$8.96K	Hold	150	–	–	﹤0.01%	2013
2023 Q1	$8.76K	Hold	150	–	–	﹤0.01%	2152
2022 Q4	$9.31K	Hold	150	–	–	﹤0.01%	1995
2022 Q3	$8K	Hold	150	–	–	﹤0.01%	2022
2022 Q2	$10K	Hold	150	–	–	﹤0.01%	1994
2022 Q1	$10K	Hold	150	–	–	﹤0.01%	2058
2021 Q4	$10K	Hold	150	–	–	﹤0.01%	2091
2021 Q3	$9K	Hold	150	–	–	﹤0.01%	2033
2021 Q2	$9K	Hold	150	–	–	﹤0.01%	2039
2021 Q1	$9K	Hold	150	–	–	﹤0.01%	2039
2020 Q4	$9K	Sell	150 -270	-64%	-$15.4K	﹤0.01%	1970
2020 Q3	$23K	Hold	420	–	–	﹤0.01%	1543
2020 Q2	$22K	Hold	420	–	–	﹤0.01%	1520
2020 Q1	$19K	Hold	420	–	–	﹤0.01%	1540
2019 Q4	$22K	Hold	420	–	–	﹤0.01%	1632
2019 Q3	$20K	Hold	420	–	–	﹤0.01%	1618
2019 Q2	$21K	Sell	420 -90	-18%	-$4.45K	﹤0.01%	1621
2019 Q1	$26K	Hold	510	–	–	﹤0.01%	1495
2018 Q4	$24K	Hold	510	–	–	﹤0.01%	1494
2018 Q3	$29K	Buy	510 +90	+21%	+$4.92K	﹤0.01%	1500
2018 Q2	$21K	Hold	420	–	–	﹤0.01%	1649
2018 Q1	$21K	Buy	420 +150	+56%	+$7.7K	﹤0.01%	1645
2017 Q4	$14K	Hold	270	–	–	﹤0.01%	1725
2017 Q3	$14K	Hold	270	–	–	﹤0.01%	1690
2017 Q2	$14K	Hold	270	–	–	﹤0.01%	1645
2017 Q1	$14K	Hold	270	–	–	﹤0.01%	1639
2016 Q4	$13K	Hold	270	–	–	﹤0.01%	1724
2016 Q3	$13K	Hold	270	–	–	﹤0.01%	1761
2016 Q2	$13K	Sell	270 -315	-54%	-$15K	﹤0.01%	1709
2016 Q1	$27K	Buy	+585	New	+$27.4K	﹤0.01%	1532
2015 Q4	–	Sell	-1,476	Closed	-$73K	–	2801
2015 Q3	$73K	Hold	1,476	–	–	﹤0.01%	1260
2015 Q2	$86K	Buy	+1,476	New	+$86.2K	﹤0.01%	1247
2014 Q4	–	Sell	-225	Closed	-$11K	–	2422
2014 Q3	$11K	Buy	+225	New	+$10.2K	﹤0.01%	1953

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Fifth Third Bancorp's IHE Position: Q2 2026 in Review

Fifth Third Bancorp increased its iShares US Pharmaceuticals ETF (IHE) stake by 3.2% in Q2 2026, buying an estimated $19.2K and bringing the position to 6,773 shares worth $671K. The position accounts for ﹤0.01% of the portfolio, ranked #1923.

Fifth Third Bancorp first reported a position in IHE in Q3 2014 and has held it in 45 quarters since. 209 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

Fifth Third Bancorp held 6,773 shares of iShares US Pharmaceuticals ETF worth $671K as of Q2 2026.
Fifth Third Bancorp bought 213 iShares US Pharmaceuticals ETF shares in Q2 2026, an estimated $19.2K.
iShares US Pharmaceuticals ETF made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #1923 holding.
Fifth Third Bancorp first reported a position in iShares US Pharmaceuticals ETF in Q3 2014 and has held it in 45 quarters since.
209 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.